Covidien plc

Covidien — Merger or Acquisition (July 2014)

26 slides from Covidien's merger presentation, Jul 31, 2014

  1. Slide 1: Town Hall Meeting

    Town Hall Meeting July 31, 2014 Omar Ishrak Chairman and CEO Medtronic, Inc. Filed by Medtronic, Inc. (SEC File No.: 001-07707) pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Covidien plc Form

  2. Slide 2: Medtronic to Acquire Covidien

    Medtronic to Acquire Covidien Creates the premier global medical technology and services company with unmatched breadth and patient reach

  3. Slide 3: About Medtronic

    About Medtronic

  4. Slide 4: Fulfilling Unmet Medical Needs

    Fulfilling Unmet Medical Needs

  5. Slide 5: The Medtronic Mission: A Shared Sense of Purpose

    The Medtronic Mission: A Shared Sense of Purpose To contribute to human welfare…alleviate pain, restore health, and extend life… To direct our growth in the areas of maximum strength and ability…to continuously build on these areas through education and knowledge… To strive without reserve for the g

  6. Slide 6: Universal Healthcare Needs

    Improve Clinical Outcomes Expand Access Optimize Cost and Efficiency Universal Healthcare Needs

  7. Slide 7: Strategies to Address Healthcare Needs

    Economic Value Globalization Strategies Therapy Innovation Universal HC needs Improve clinical outcomes Expand access Optimize cost and efficiency Strategies to Address Healthcare Needs

  8. Slide 8: Three Business Groups Address Broad Spectrum of Diseases

    Three Business Groups Address Broad Spectrum of Diseases The data in this chart has been intentionally rounded to the nearest whole percentage and therefore does not sum to 100%. Cardiac Rhythm & Heart Failure 30% Coronary & Structural Heart 18% Aortic & Peripheral 5% Diabetes 9% Surgical Technologi

  9. Slide 9: Strategic Fit

    Strategic Fit

  10. Slide 10: Combination Results in Strategic Diversification

    Combination Results in Strategic Diversification Surgical Solutions Respiratory & Patient Care Surgical Solutions Respiratory & Patient Care

  11. Slide 11: A Strong Strategic Fit

    Delivering strong launch cadence of meaningful therapies and procedures Addressing the inequities in healthcare access globally Becoming a leader in value-based healthcare by incorporating EV into our DNA Uniquely positioned to expand our industry- leading franchises through our three differentiated

  12. Slide 12: Three Key Benefits for Medtronic and Covidien

    Three Key Benefits for Medtronic and Covidien Therapy Innovation Therapy Innovation 1. Strengthen and enhance Peripheral Vascular and Neuroscience portfolios 2. Leverage adjacencies in Medtronic Surgical Technologies and Covidien Surgical Solutions 3. Accelerate market adoption of early stage Covidi

  13. Slide 13: Covidien Expertise Creates Broader Offering in Peripheral Vascular Disease Management

    Covidien Expertise Creates Broader, More Compelling Offering in Peripheral Vascular Disease Management Strength in Aortic Disease Management Strength and Product Breadth in Peripheral Vascular Disease Management Combined Businesses Will Provide Opportunity to Accelerate Growth Augmented by Therapy I

  14. Slide 14: Combined Company Immediately Accelerates Ability to Expand Global Access

    Combined Company Immediately Accelerates Ability to Expand Global Access countries 150 + locations 300 + combined EM revenue $3.7B Broader presence facilitates more rapid expansion Covidien products such as surgical tools and capital equipment are adopted earlier in hospitals, becoming a base for Me

  15. Slide 15: Opportunities to Become Robust Integrated Health Solutions Partner

    Cath Lab Managed Services (Europe) Cardiac & Vascular Line Administrator (U.S.) General Surgery Line Administrator (U.S.) General Surgery Managed Services (Europe) Opportunities to Become Robust Unmatched Integrated Health Solutions Partner Economic Value Cardiocom Covidien Sensors Value primarily r

  16. Slide 16: Integration Guidelines

    Integration Guidelines

  17. Slide 17: Guiding Principles for Integration

    Guiding Principles for Integration • Continue to act as independent companies until transaction close • Keep focus and protect current business momentum in our respective companies • Plan for integration now to be ready for Day 1 post-close • Focus on creating lasting value beyond stated cost synerg

  18. Slide 18: Integration Team Structure

    Integration Team Structure Medtronic Medtronic Geoff Martha Bill Burke Medtronic Steering Committee Medtronic Medtronic Medtronic Medtronic Medtronic Medtronic Medtronic Medtronic Medtronic Medtronic Medtronic Medtronic Medtronic Medtronic Cross-functional teams Commercial teams Functional teams Med

  19. Slide 19: Combined Impact

    Combined Impact

  20. Slide 20: Accelerating Covidien Early Stage Therapies

    Accelerating Covidien Early Stage Therapies Interventional Lung: For Lung Cancer Interventional GI (Barrett's): For Barrett's Esophagus (pre-cancerous) Stroke: SWIFT PRIME Clinical Trial Open to Minimally Invasive Surgery: e.g. Bariatric Minimally Invasive Surgery Capnography: CO Monitoring 2

  21. Slide 21: Transforming Healthcare Around the World to Improve More Lives Together

    Transforming Healthcare Around the World to Improve More Lives Together: Every seconds $27 Billion Healthcare Leader 87,000+ Employees Life-Changing Impact for Millions of Patients

  22. Slide 22: Q&A

    Q&A ?

  23. Slide 23: No Offer or Solicitation

    NO OFFER OR SOLICITATION This communication is not intended to and does not constitute an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation to purchase or subscribe for any securities or the solicitation of any vote or approval in any jurisdiction pursuant to the

  24. Slide 24: Cautionary Statement Regarding Forward-Looking Statements

    Cautionary Statement Regarding Forward-Looking Statements Statements contained in this communication that refer to New Medtronic’s, Medtronic's and/or Covidien’s estimated or anticipated future results, including estimated synergies, or other non-historical facts are forward-looking statements that

  25. Slide 25: Statement Required by the Irish Takeover Rules

    Statement Required by the Irish Takeover Rules The directors of Medtronic accept responsibility for the information contained in this document. To the best of the knowledge and belief of the directors of Medtronic (who have taken all reasonable care to ensure that such is the case), the information

  26. Slide 26: Town Hall Meeting

    Town Hall Meeting Omar Ishrak Chairman and CEO Medtronic, Inc.

Covidien — Merger or Acquisition (July 2014) on 6ix